To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
NOD2 Knockout MCF-7 Cell Line
Immortalized Cell
MCF-7 cell line with homozygous knockout of NOD2.
This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2026
Trpml1 Knockout RAW264.7 Cell Line
Immortalized Cell
RAW264.7 cell line with homozygous knockout of Trpml1.
This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2026
Nod2 Knockout RAW264.7 Cell Line
Immortalized Cell
RAW264.7 cell line with homozygous knockout of Nod2.
This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2026
Usp30 Knockout RAW264.7 Cell Line
Immortalized Cell
RAW264.7 cell line with homozygous knockout of Usp30.
This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2026
TRPML1 Antibody
Antibody
Rabbit monoclonal antibody directed against mouse TRPML1. Developed for use in immunoblotting and immunocytochemistry applications.
This antibody development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2027
OGA Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations heterozygous and homozygous knockout of OGA.
This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2026
PARP1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations heterozygous and homozygous knockout of PARP1.
This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2026
Human O-GlcNAc T72 aSyn ELISA
Assay
ELISA kit for quantification of alpha-synuclein with O-GlcNAc on Threonine72 (O-GlcNAc T72 aSyn).
This assay development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Estimated availability: Late 2027
NOD2 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse NOD2. Developed for use in immunoblotting, immunocytochemistry, and immunohistochemistry applications.
This antibody development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2027
USP30 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse USP30. Developed for use in immunocytochemistry, immunohistochemistry, and immunoprecipitation applications.
This antibody development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2027
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic